[
    [
        {
            "time": "",
            "original_text": "速读社丨齐鲁三款药过评 布罗舒单抗在华上市申请进入“在审批”",
            "features": {
                "keywords": [
                    "齐鲁",
                    "药品过评",
                    "布罗舒单抗",
                    "上市申请"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "速读社丨齐鲁三款药过评 布罗舒单抗在华上市申请进入“在审批”",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德现2笔大宗交易 共成交573.12万元",
            "features": {
                "keywords": [
                    "药明康德",
                    "大宗交易",
                    "成交金额"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德现2笔大宗交易 共成交573.12万元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【权益变动】药明康德(02359-HK)被摩根大通减持22.6058万股 减持股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "摩根大通",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【权益变动】药明康德(02359-HK)被摩根大通减持22.6058万股 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "大和：首予药明康德(02359)“跑赢大市”评级 目标价174港元",
            "features": {
                "keywords": [
                    "药明康德",
                    "大和",
                    "跑赢大市",
                    "目标价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "大和：首予药明康德(02359)“跑赢大市”评级 目标价174港元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：加配弹性品种 稳守核心资产",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "加配",
                    "弹性品种",
                    "核心资产"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：加配弹性品种 稳守核心资产",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "药石科技(300725)事件点评：定增落地 全球新型分子砌块龙头进入发展新时期",
            "features": {
                "keywords": [
                    "药石科技",
                    "定增",
                    "分子砌块",
                    "龙头",
                    "发展新阶段"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药石科技(300725)事件点评：定增落地 全球新型分子砌块龙头进入发展新时期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "2021年医药行业投资策略：CXO板块快速前行，创新药龙头逆境重生，给予“推荐”评级",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "CXO板块",
                    "创新药",
                    "龙头",
                    "推荐评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2021年医药行业投资策略：CXO板块快速前行，创新药龙头逆境重生，给予“推荐”评级",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "药明康德(02359-HK)昨日股价创52周新高 大和首予目标价174港元",
            "features": {
                "keywords": [
                    "药明康德",
                    "股价",
                    "52周新高",
                    "大和",
                    "目标价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(02359-HK)昨日股价创52周新高 大和首予目标价174港元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]